Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
Moderna logo
ModernaMRNA
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
——
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%—
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's available for sale securities debt securities current?
Ultragenyx Pharmaceutical (RARE) reported available for sale securities debt securities current of $238M in Q1 2026.
How has Ultragenyx Pharmaceutical's available for sale securities debt securities current changed year-over-year?
Ultragenyx Pharmaceutical's available for sale securities debt securities current decreased by 35.2% year-over-year, from $367.39M to $238M.
What is the long-term trend for Ultragenyx Pharmaceutical's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's available for sale securities debt securities current has grown at a -11.9% compound annual growth rate (CAGR), from $488.01M to $259M.